Does preoperative administration of allopurinol protect the lungs from ischemia-reperfusion injury occuring during cardiopulmonary bypass?

Basit Öğe Kaydı
dc.contributor.authorGormus, Z., I
dc.contributor.authorCelik, J. B.
dc.contributor.authorErgene, N.
dc.contributor.authorGormus, N.
dc.contributor.authorBaltaci, A. K.
dc.date.accessioned2020-03-26T18:41:32Z
dc.date.available2020-03-26T18:41:32Z
dc.date.issued2013
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractBackground: It is investigated whether preoperative allopurinol administration protects lung injury induced by cardiopulmonary bypass (CPB). Methods: Sixty patients with coronary artery disease who need elective coronary artery bypass grafting operations by using CPB were taken into this study. They were divided into two groups; control and allopurinol. Allopurinol (300 mg/day) was administered to the latter group during the preoperative period of 5 days. Standard CPB procedures were used in all cases. Blood was sampled for TNF-alpha, IL-6, IL-8, IL-10 before anesthesia (T0), after anesthesia and before skin incision (T1), before CPB (T2), after aortic declamping (T3), at the end of CPB (T4), 6 hours after operation (T5), 12 hours after operation (T6), and 24 hours after operation (T7). Pulmonary function test (PFT) was performed before and following the 6th day of operation. Results: TNF-alpha, IL-6, IL-8 increased in both groups at T3, T4, T5 and T6 compared to control (p<0.05). TNF-alpha, IL-6, and IL-8 levels were lower in group A at T3, T4, T5 and T6 (p<0.05). Creatinin phosphokinase (CK) levels were lower in group A at T6 (p<0.05). CK-MB levels were lower in group A than in group C (p<0.05). Pulmonary function test (PFT) did not yield any differences between the groups. Conclusions: Preoperative allopurinol administration decreases the inflammation and myocardial injury according to biochemical markers of ischemia reperfusion injury. However, this biochemical success does not rebound to PFT (Tab. 5, Ref. 15). Full Text in PDF www.elis.sk.en_US
dc.identifier.doi10.4149/BLL_2013_118en_US
dc.identifier.endpage565en_US
dc.identifier.issn0006-9248en_US
dc.identifier.issn1336-0345en_US
dc.identifier.issue10en_US
dc.identifier.pmid24156678en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage561en_US
dc.identifier.urihttps://dx.doi.org/10.4149/BLL_2013_118
dc.identifier.urihttps://hdl.handle.net/20.500.12395/29391
dc.identifier.volume114en_US
dc.identifier.wosWOS:000331063100003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherCOMENIUS UNIVen_US
dc.relation.ispartofBRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectcardiopulmonary bypassen_US
dc.subjectlungen_US
dc.subjectischemia-reperfusion injuryen_US
dc.subjectallopurinolen_US
dc.titleDoes preoperative administration of allopurinol protect the lungs from ischemia-reperfusion injury occuring during cardiopulmonary bypass?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu